



## **Biomea Fusion to Participate in Jefferies Healthcare Conference**

June 2, 2022

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference. The fireside chat will take place on Wednesday, June 8<sup>th</sup> at 2:30pm Eastern Time.

A live webcast of the fireside chat can be accessed at <https://investors.biomeafusion.com/> and will be available for 90 days following the presentation.

### **About Biomea Fusion**

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION<sup>TM</sup> System to advance a pipeline of covalent-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion's goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.

### **Contact:**

Van Sandwick  
Director, Investor Relations & Corporate Development  
[vsandwick@biomeafusion.com](mailto:vsandwick@biomeafusion.com)  
(650) 460-7759